Enalaprilat , ≥99% , 76420-72-9

Synonym(s):
(2S)-1-[(2S)-2-[[(1S)-1-Carboxy-3-phenyl-propyl]amino]propanoyl]pyrrolidine-2-carboxylic acid;(2S)-1-[(2S)-2-[[(1S)-1-Carboxy-3-phenyl-propyl]amino]propanoyl]pyrrolidine-2-carboxylic acid;N-[(1S)-1-Carboxy-3-phenylpropyl]-L-alanyl-L-proline;Enalaprilat dihydrate;Vasotec

CAS NO.：76420-72-9

Empirical Formula: C18H24N2O5

Molecular Weight: 348.39

MDL number: MFCD00865786

EINECS: 278-459-3

PRODUCT Properties

• Melting point: 148-151°C
• alpha: D -67.0° (0.1M HCl)
• Boiling point: 601.0±55.0 °C(Predicted)
• Density: 1.286±0.06 g/cm3(Predicted)
• storage temp.: 2-8°C
• solubility: Very slightly soluble or slightly soluble in water, sparingly soluble in methanol, practically insoluble in acetonitrile.
• pka: pKa 2.30 (Uncertain);3.39 (Uncertain)
• Water Solubility: Soluble in water with heating (~60°C)

Description and Uses

Enalaprilat is the diacid active metabolite of enalapril. As an injectable ACE inhibitor, it is reportedly useful in the treatment of uncomplicated accelerated hypertension and hypertensive emergencies. Enalaprilat is more effective in reducing blood pressure in the elderly than in the young, despite the fact that renin activity is lower in old age.

Enalapril is a ACE (angiotensin-converting enzyme) inhibitor, suggested to be more potent than Captopril (sc-200566). Studies indicate that Enalapril downregulates the expression of IL-β, IL-6, and NF-κB. Further studies show that Enalapril upregulates the expression of VEGF and heme oxygenase-1. Enalaprilat reports demonstrate that the compound has some antioxidant activity, which does not include the PKC-NADPH oxidase pathway.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302
• Precautionary statements: P264-P270-P301+P312-P330-P501
• Hazard Codes: Xn
• Risk Statements: 22
• WGK Germany: 2